摘要
新新肝康片系我院研制的治疗病毒性肝炎的一种新药，该药的研究系根据病毒性肝炎的发病机理和中医辩证施治的原则。在总结临床经验的基础上，将祖国传统医学和现代医药学理论相结合，科学研制的一种纯中药制剂。该药具有扶正去邪、清热解毒、活血化瘀、强肝益肝等作用。为了给新新肝康片的临床安全性提供可靠的依据，本文考察了新新肝康片对四氯化碳、Ｄ－氨基半乳糖致小鼠急性肝损伤［１］的保护作用及该药物对心、肾、脾脏器的生化指标等项目。
Xinxin Gankang tablet(XXGK),a preparation of Chinese materia medica,is a new drug for treating viral hepatitis.It is developed on the basis of pathogenesis of viral hepatitis and basic theories of traditional Chinese medicine, and has the effects of strengthening the body resistance to eliminate pathogenic factors,clearing away heat and toxic material, promoting blood circulation by removing blood stasis and exerting a tonic effect on liver. In order to provide the basis of security in clinical use,we carried out an experimental study on the protective effect of XXGK on rat' s acute hepatic injury induced by CCI4 and D-galactosamine as well as the changes in biochemical parameters of heart,kidney and spleen after administration of XXGK.
出处
《中国药房》
CAS
CSCD
1996年第5期204-205,共2页
China Pharmacy
关键词
四氯化碳
D-氨基半乳糖
新新肝康片
急性肝损伤
carbon tetrachloride D-galactosamine Xinxin Gankang tablet acute hepatic injury
